EUVIMEDEUVIMED entdecken
Crossref

Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy

Jacopo Giuliani, Beatrice Mantoan, Daniela Mangiola, Marco Muraro, Giuseppe Napoli, Marina Tommasi, Francesco Fiorica, Marta Mandarà

Clinical Colorectal Cancer · 2024

DOI: 10.1016/j.clcc.2023.10.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Colorectal Cancer, 2024. Verfasst von Jacopo Giuliani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Azienda ULSS 9 Scaligera, Legnago (VR), Italy. Electronic address: jacopo.giuliani@aulss9.veneto.it. Hauptthemen laut MEDLINE: Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Pyrrolidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colonic NeoplasmsRectal NeoplasmsColorectal NeoplasmsPyrrolidinesThymineHumansBevacizumabTrifluridineCost-Benefit AnalysisDrug CombinationsAntineoplastic Combined Chemotherapy ProtocolsUracil

Stichwörter der Autor:innen

BevacizumabCost of drugsMetastatic colorectal cancerThird-lineTrifluridine/tipiracil

Substanzen

tipiracilBevacizumabTrifluridineDrug CombinationsUracilPyrrolidinesThymine

Autor:innen und Institutionen

  • Department of Oncology, Azienda ULSS 9 Scaligera, Legnago (VR), Italy. Electronic address: jacopo.giuliani@aulss9.veneto.it.
  • Department of Diagnostic Imaging, Azienda ULSS 9 Scaligera, Legnago (VR), Italy.
  • Department of Oncology, Azienda ULSS 9 Scaligera, Legnago (VR), Italy.
  • Pharmaceuthical Department, Azienda ULSS 9 Scaligera, Legnago (VR), Italy.

Zitieren

APA

Giuliani, J., Mantoan, B., Mangiola, D., Muraro, M., Napoli, G., Tommasi, M., Fiorica, F., & Mandarà, M. (2024). Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2023.10.005

Vancouver

Giuliani J, Mantoan B, Mangiola D, Muraro M, Napoli G, Tommasi M, et al. Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy. Clinical Colorectal Cancer. 2024. doi:10.1016/j.clcc.2023.10.005

BibTeX
@article{Giuliani2024,
  author = {Giuliani, Jacopo and Mantoan, Beatrice and Mangiola, Daniela and Muraro, Marco and Napoli, Giuseppe and Tommasi, Marina and Fiorica, Francesco and Mandarà, Marta},
  title = {Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy},
  journal = {Clinical Colorectal Cancer},
  year = {2024},
  doi = {10.1016/j.clcc.2023.10.005}
}
Kostenlos starten →